刺山柑总生物碱对系统性硬皮病小鼠Wnt2、Wnt3a及β-catenin的影响  

Effects of total alkaloids from Capparis spinosa on Wnt2,Wnt3a andβ-catenin in mice with systemic scleroderma

作　　者：赵宇涵 康小龙 何承辉 ZHAO Yu-han;KANG Xiao-long;HE Cheng-hui(Dept of Pharmacology, Xinjiang Medical University, Urumqi 830000, China;Hospital of Chinese Medicine Affiliated to Xinjiang Medical University, Urumqi 830002, China;Xinjiang Medicine Research Institute, Urumqi 830004, China)

机构地区：[1]新疆医科大学药学院,新疆乌鲁木齐830000 [2]新疆维吾尔自治区中医医院,新疆乌鲁木齐830002 [3]新疆维吾尔自治区药物研究所,新疆乌鲁木齐830004

出　　处：《中国药理学通报》2021年第10期1474-1478,共5页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金资助项目(No 81760560)。

摘　　要：目的通过观察系统性硬皮病(systemic scleroderma,SSc)小鼠经刺山柑总生物碱治疗后,其Wnt通路中Wnt2、Wnt3a及β-catenin的表达水平,探讨其对SSc Wnt通路的调控作用。方法BALB/c小鼠皮下注射博来霉素复制SSc模型。给予不同量刺山柑总生物碱,以及阳性药青霉胺干预。取皮肤,Western blot测Wnt3a、β-catenin蛋白表达,q-RT PCR测Wnt2 mRNA表达,免疫组化检测Wnt3a蛋白表达。结果刺山柑总生物碱中、高剂量组可明显降低SSc小鼠皮肤β-catenin的表达水平(P<0.05),各剂量药物组可明显降低Wnt2、Wnt3a蛋白表达(P<0.01)。结论刺山柑总生物碱可降低SSc小鼠皮肤Wnt2、Wnt3a和β-catenin表达,对其过表达的Wnt通路有一定抑制作用。Aim To observe the expression of Wnt2,Wnt3a andβ-catenin in the Wnt pathway of systemic scleroderma(SSc)mice treated with total alkaloids of Capparis spinosa,and to explore the regulation of Wnt2,Wnt3a andβ-catenin on SSC Wnt pathway.Methods BALB/c mice were injected with bleomycin to establish SSC model.Different doses of total alkaloids from Capparis spinosa and penicillamine were administered.The expressions of Wnt3a andβ-catenin were detected by Western blot,Wnt2 mRNA expression by q-RT PCR and Wnt3a protein expression by immunohistochemistry.Results The expression level ofβ-catenin in skin of SSC mice significantly decreased in the medium and high dose groups(P<0.05),and the protein expressions of Wnt2 and Wnt3a significantly decreased in all doses of total alkaloids of Capparis spinosa(P<0.05 or P<0.01).Conclusions The total alkaloids of Capparis spinosa can reduce the expression of Wnt2,Wnt3a andβ-catenin in SSc mice,and inhibit the overexpression of Wnt pathway in SSc mice.

关 键 词：系统性硬皮病 纤维化 刺山柑总生物碱 Wnt2 WNT3A Β-CATENIN 

分 类 号：R-332[医药卫生] R284.1